GARDEN CITY, N.Y. and REHOVOT, Israel, Nov. 05, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTCQB: AITB), a
clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of
patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced that Steven
Lisi, CEO will present at the upcoming Canaccord Genuity Medical Technologies & Diagnostics Forum being held on November 15, 2018
at the Westin Grand Central Hotel, New York, NY.
2018 Canaccord Genuity Medical Technologies & Diagnostics Forum
Date:
Thursday, November 15, 2018
Time:
8:30 am Eastern Time
Location:
Westin Grand Central Hotel, New York
Webcast: http://wsw.com/webcast/canaccord32/aitb
About AIT Therapeutics Inc.
AIT Therapeutics Inc. is a clinical-stage medical device and biopharmaceutical company using nitric oxide (NO) to treat respiratory
and other diseases. The Company is currently applying its therapeutic expertise to treat lower respiratory tract infections that
are not effectively addressed with current standards of care, as well as pulmonary hypertension, in various settings. AIT is
currently advancing its revolutionary NO Generator and Delivery System in clinical trials for the treatment of bronchiolitis and
severe lung infections such as nontuberculous mycobacteria (NTM). For more information, visit www.AIT-Pharm.com.
Forward-Looking Statement
This press release contains “forward-looking statements.” Forward-looking statements include statements about our
expectations, beliefs, or intentions regarding our product offerings, business, financial condition, results of operations,
strategies or prospects. You can identify such forward-looking statements by the words “expects,” “intends,” “plans,” “projects,”
“believes,” “estimates,” “likely,” “goal,” “assumes,” “targets” and similar expressions and/or the use of future tense or
conditional constructions (such as “will,” “may,” “could,” “should” and the like) and by the fact that these statements do not
relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events,
activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet
occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ
materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are
only predictions and reflect our views as of the date they are made with respect to future events and financial performance. Many
factors could cause our actual activities or results to differ materially from the activities and results anticipated in
forward-looking statements, including risks related to: our approach to discover and develop novel drugs, which is unproven and may
never lead to marketable products; our ability to fund and the results of further pre-clinical and clinical trials; obtaining,
maintaining and protecting intellectual property utilized by our products; our ability to enforce our patents against infringers
and to defend our patent portfolio against challenges from third parties; our ability to obtain additional funding to support our
business activities; our dependence on third parties for development, manufacture, marketing, sales, and distribution of products;
the successful development of our product candidates, all of which are in early stages of development; obtaining regulatory
approval for products; competition from others using technology similar to ours and others developing products for similar uses;
our dependence on collaborators; and our short operating history. We undertake no obligation to update, and we do not have a policy
of updating or revising, these forward-looking statements, except as required by applicable law.
CONTACT
Steven Lisi, Chief Executive Officer
AIT Therapeutics, Inc.
Steve@AIT-Pharm.com
Bob Yedid
LifeSci Advisors, LLC
Bob@LifeSciAdvisors.com
(646) 597-6989
